Treatments policy

• Health & Medicine

Cancer waiting times: Latest updates and analysis

Get the latest updates and analysis on NHS cancer waiting times in England, and learn what it means for people affected by cancer Get the latest updates and analysis on NHS cancer waiting times in England, and learn what it means for people affected by cancer

11 April 2024

• Health & Medicine
• Opinion

People who’ve had radiotherapy shape our new policy calls

On the back of a recent survey, our new policy position statement on radiotherapy turns patient experiences into recommendations for the Government and the NHS. On the back of a recent survey, our new policy position statement on radiotherapy turns patient experiences into recommendations for the Government and the NHS.

4 May 2023

• Health & Medicine
• Opinion

The 10-year cancer plan: is improving cancer survival still a priority for this Government?  

Cancer is a fixable problem – but we need the right leadership, a robust plan and sufficient funding, writes Michelle Mitchell, our chief executive officer. Cancer is a fixable problem – but we need the right leadership, a robust plan and sufficient funding, writes Michelle Mitchell, our chief executive officer.

8 December 2022

• Health & Medicine

New targeted treatment for early breast cancer could reduce risk of relapse

A targeted cancer drug has been approved to treat some people with breast cancer that has a high-risk of returning. A targeted cancer drug has been approved to treat some people with breast cancer that has a high-risk of returning.

21 July 2022

• Health & Medicine

Immunotherapy treatment fast tracked to treat lung cancer patients in England

Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England. Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England.

28 January 2022

• Health & Medicine

How will new cancer medicines be approved in the future?

In the last decade, many more cancer drugs have become available compared to what we’ve seen previously. This has led to more cancer treatment options, but it has also led to more uncertainty about drugs’ clinical benefit and cost-effectiveness. How can this be addressed? In the last decade, many more cancer drugs have become available compared to what we’ve seen previously. This has led to more cancer treatment options, but it has also led to more uncertainty about drugs’ clinical benefit and cost-effectiveness. How can this be addressed?

2 December 2021